ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

izalontamab brengitecan

Also written as “BL-B01D1”, “Iza-bren” and “BMS-986507”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Small Cell Lung Carcinoma · Breast Neoplasms · Nasopharyngeal Carcinoma, led by 2 companies.

Drug pageIzalontamab brengitecan: every studyAll 59 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 25, 202355 company-led studies, 55 open or runningLicense: SystImmune (Biokin) → Bristol Myers Squibb, Dec 2023Next primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Biokin Pharmaceutical5050 open or runningphase 3since Oct 25, 2023Jan 4, 2022Nov 2026phase 3 · NCT06118333
Bristol-Myers Squibbits history only55 open or runningphase 3since Apr 8, 2025Sep 26, 2024Mar 13, 2028phase 3 · NCT06926868
  • Named in Bristol-Myers Squibb’s own pipeline as iza-bren, phase 3, as of Oct 29, 2026 (source).

Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Sichuan Biokin Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 30 earlier studies, Jan 4, 2022 to Jan 16, 2025.

  1. Aug 6, 2023Named izalontamab brengitecanINNProposed as its International Nonproprietary Name in WHO's List 129 · before, BMS-986507
  2. Dec 11, 2023Bristol Myers Squibb licensed it from SystImmune (Biokin)LicenseOutside mainland China, developed and sold jointly in the US · announced · SystImmune and Bristol Myers Squibb (release)
  3. Feb 16, 20252 phase 3 studiesNCT06838273, NCT06857175
  4. Apr 28, 2025Phase 2 study in Kidney NeoplasmsNCT06962787 · 260 planned · China
  5. May 11, 20252 phase 2 studiesNCT06978114, NCT06986785
  6. May 20, 2025Phase 3 study in Carcinoma, Ovarian EpithelialNCT06994195 · 450 planned · China
  7. Jun 20, 2025Phase 2 study in Uterine Cervical NeoplasmsNCT07054567 · 96 planned · China
  8. Mar 25, 2026Phase 3 study in Small Cell Lung CarcinomaNCT07502300 · 562 planned · China
  9. Apr 21, 2026Phase 3 study in Esophageal Squamous Cell CarcinomaNCT07554456 · 90 planned · China
  10. May 6, 2026Phase 3 study in Biliary Tract NeoplasmsNCT07582315 · 538 planned · China
  11. Jun 7, 20264 phase 3 studiesNCT07640789, NCT07648914, NCT07642024 and 1 more
  12. Jul 20, 20263 phase 3 studiesNCT07729956, NCT07739199, NCT07739186
  13. Aug 20, 2026Phase 3 study in Nasopharyngeal CarcinomaNCT07783321 · 404 planned · China
  14. Aug 27, 2026Phase 2 study in Nasopharyngeal CarcinomaNCT07797881 · 60 planned · China
  15. Sep 14, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07827261 · 36 planned · China
  16. Oct 9, 2026Primary completion moved from 2026-08 to 2027-06Date moved laterphase 2 · +10 months · NCT06498986

Ahead

  1. Nov 2026Primary completion: phase 3 study in Nasopharyngeal CarcinomaNCT06118333
  2. Dec 2026Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT06500026
  3. Dec 2026Primary completion: phase 2 study in Triple Negative Breast NeoplasmsNCT06471205
  4. Dec 2026Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT06437509

TargetBeta

“A dual-targeted antibody-drug conjugate (ADC) consisting of a bispecific antibody directed against both the epidermal growth factor receptor (EGFR; HER1; ErbB1) and the epidermal growth factor receptor 3 (HER3; ErbB3) conjugated, via a cathepsin-B cleavable linker, to the camptothecin derivative …”NCIt, read by Claude
“A dual-targeted antibody-drug conjugate (ADC) consisting of a bispecific antibody directed against both the epidermal growth factor receptor (EGFR; HER1; ErbB1) and the epidermal growth factor receptor 3 (HER3; ErbB3) ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418ruleavenzo-therapeutics-incphase 21
CS5007ruleCStone Pharmaceuticalsphase 11

Studies

All 50 Sichuan Biokin Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07827261Carcinoma, Non-Small-Cell Lung · China2Not yet recruitingDec 202836
NCT07797881Nasopharyngeal Carcinoma · China2Not yet recruitingDec 203060
NCT07783321Nasopharyngeal Carcinoma · China3Not yet recruitingDec 2033404
NCT07739199Squamous Non-small-cell Lung Cancer · China3RecruitingDec 2029326
NCT07739186Non-squamous Non-small Cell Lung Cancer · China3RecruitingDec 2029166
NCT07729956Triple Negative Breast Neoplasms · China3RecruitingDec 2029436
NCT07648914Breast Neoplasms · China3RecruitingDec 2028446
NCT07642024Carcinoma, Non-Small-Cell Lung · China3RecruitingDec 203290
NCT07641855Castration-resistant Prostate Cancer · China3Not yet recruitingDec 2028180
NCT07640789Carcinoma, Non-Small-Cell Lung · China3RecruitingDec 2030418
NCT07582315Biliary Tract Neoplasms · China3RecruitingDec 2028538
NCT07554456Esophageal Squamous Cell Carcinoma · China3RecruitingDec 202890
NCT07502300Small Cell Lung Carcinoma · China3RecruitingDec 2029562
NCT07054567Uterine Cervical Neoplasms · China2RecruitingMay 202796
NCT06994195Carcinoma, Ovarian Epithelial · China3RecruitingJun 2027450
NCT06986785Advanced Hepatocellular Carcinoma · China2RecruitingMay 202774
NCT06978114Advanced Biliary Tract Cancer · China2RecruitingMay 202746
NCT06962787Kidney Neoplasms · China2RecruitingMay 2027260
NCT06857175Carcinoma, Transitional Cell · China3Active, not recruitingJun 2027515
NCT06838273Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingDec 2028724
NCT06787664Chordoma · China2Active, not recruitingJun 202727
NCT06598787Glioblastoma · China2RecruitingOct 202620
NCT06500026Small Cell Lung Carcinoma · China3Active, not recruitingDec 2026722
NCT06498986Carcinoma, Non-Small-Cell Lung · China2Active, not recruitingJun 202776
NCT06475300Carcinoma, Non-Small-Cell Lung · China2RecruitingJun 2027570
NCT06471205Triple Negative Breast Neoplasms · China2RecruitingDec 202652
NCT06437522Squamous Cell Carcinoma of Head and Neck · China2RecruitingJun 202746
NCT06437509Small Cell Lung Carcinoma · China2RecruitingDec 202666
NCT06405425Carcinoma, Transitional Cell · China2RecruitingDec 202652
NCT06382142Triple Negative Breast Neoplasms · China3Active, not recruitingJan 13, 2026418
NCT06382129Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingDec 2026698
NCT06382116Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingAug 2026432
NCT06343948HR+HER2- Breast Cancer · China3Active, not recruitingAug 2026383
NCT06304974Esophageal Squamous Cell Carcinoma · China3Active, not recruitingOct 17, 2025497
NCT06118333Nasopharyngeal Carcinoma · China3Active, not recruitingNov 2026386
NCT06042894Breast Neoplasms · China2RecruitingDec 202658
NCT06006169Squamous Cell Carcinoma of Head and Neck · China2RecruitingDec 2026186
NCT06008054Esophageal Neoplasms · China2RecruitingDec 2026376
NCT05990803Uterine Cervical Neoplasms · China2RecruitingDec 2026130
NCT05965856Carcinoma, Transitional Cell · China2RecruitingDec 202652
NCT05956587Carcinoma, Non-Small-Cell Lung · China2RecruitingDec 2026121
NCT05983432Carcinoma, Non-Small-Cell Lung · United States, France, Italy and more1RecruitingApr 20, 2030540
NCT05924841Small Cell Lung Carcinoma · China2RecruitingDec 2026100
NCT05880706Carcinoma, Non-Small-Cell Lung · China2Active, not recruitingJul 2027198
NCT05803018Ovarian Neoplasms · China2RecruitingDec 202638
NCT05785039Urologic Neoplasms · China2RecruitingDec 202676
NCT05470348Breast Neoplasms · China1RecruitingDec 202636
NCT05262491Digestive System Neoplasms · China1RecruitingDec 202696
NCT05393427Carcinoma, Renal Cell · China1Active, not recruitingDec 20254
NCT05194982Neoplasm Metastasis · China1RecruitingDec 2026570

How it is read

Names in the registry

  • “BL-B01D1”, 49 entries
  • “Iza-bren”, 4 entries
  • “BMS-986507”, 1 entry
  • “BL-B01D1 for Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.